Citations

Mayo Clinic

Showing 10 of 108572 citations.

Extrachromosomal DNA Couples with ATM-mediated DNA Damage Response for Genome Instability in Tumors
Gan, Haiyun , Zhou, Jiaqi , Zhang, Yang , Hu, Suili, Deng, Zhiwen , Xu, Yajing, Chen, Jinyi , Yue, Zhen , Yao, Sitong , Tian, Congcong , Wen, Qing , Yan, Lixia , Depies, Olivia M , Liang, Xiao‐Huan , Liu, Xiangyu , Kang, Xing, Li, Xinran , Deng, Zhiwen, Wu, Yu-Chun , Wang, Nan , Chen, Liangming , Yue, Zhen, Yao, Yuan , Yang, Xinran , Tian, Congcong, Liang, Xiaoyan , Chan, Kui Ming , Dai, Junbiao , Wang, Zhiquan , Yu, Chuanhe , Li, Gang

No container title available | January 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3708982/v1 Get It

Abstract Extrachromosomal DNA (ecDNA) drives the evolution of cancer cells by conferring survival advantages over normal cells. However, the functional importance of ecDNA replication and maintenance is yet to be evaluated, and the molecular components that contributed to these processes remain largely unknown. Here, using CRISPR-C (circularization of genes and chromosomes by CRISPR) technology and synthetic circular DNA mimicking ecDNA identified in tumors, we generated ecDNA-positive (ecDNA+) cell models. Using these models, we identified the proteins involved in ecDNA replication and maintenance and found DNA damage response (DDR)-related pathways were significantly enriched. We further demonstrated that ecDNA replication led to increased DDR and genome instability and DDR was also essential for ecDNA maintenance, consistent with observations that ecDNA+ tumors exhibited higher DDR scores than ecDNA-negative (ecDNA–) tumors in patients. ATM, MDC1, and CHK2, but not ATR, were activated in ecDNA+ cells compared to ecDNA– cells. Moreover, ecDNA+ cells were more sensitive to ATM and CHK2 inhibition. We further found that type II topoisomerase TOP2B and DNA ligase III (LIG3) were critical regulators for ecDNA replication and maintenance and related DDR. In summary, our findings of the reciprocal interactions between ecDNA and DDR provide new insights into detection and therapy for ecDNA+ tumors.
Corticosteroids in Sepsis and Septic Shock: A Systematic Review, Pairwise, and Dose-Response Meta-Analysis
Pitre, Tyler, Drover, Katherine, Chaudhuri, Dipayan , Zeraaktkar, Dena, Menon, Kusum , Jayaprakash, Namita , Nei, Andrea M. , Gershengorn, Hayley Beth , Spencer-Segal, Joanna L. , Pastores, Stephen M. , Annane, Djillali , Rochwerg, Bram

Critical Care Explorations | January 23, 2024 | Volume: 6 | Issue: 1 | Pages: e1000

10.1097/cce.0000000000001000 | PMID 38250247 Get It

OBJECTIVES: To perform a systematic review and meta-analysis to assess the efficacy and safety of corticosteroids in patients with sepsis. DATA SOURCES: We searched PubMed, Embase, and the Cochrane Library, up to January 10, 2023. STUDY SELECTION: We included randomized controlled trials (RCTs) comparing corticosteroids with placebo or standard care with sepsis. DATA EXTRACTION: The critical outcomes of interest included mortality, shock reversal, length of stay in the ICU, and adverse events. DATA ANALYSIS: We performed both a pairwise and dose-response meta-analysis to evaluate the effect of different corticosteroid doses on outcomes. We used Grading of Recommendations Assessment, Development and Evaluation to assess certainty in pooled estimates. DATA SYNTHESIS: We included 45 RCTs involving 9563 patients. Corticosteroids probably reduce short-term mortality (risk ratio [RR], 0.93; 95% CI, 0.88–0.99; moderate certainty) and increase shock reversal at 7 days (RR, 1.24; 95% CI, 1.11–1.38; high certainty). Corticosteroids may have no important effect on duration of ICU stay (mean difference, –0.6 fewer days; 95% CI, 1.48 fewer to 0.27 more; low certainty); however, probably increase the risk of hyperglycemia (RR, 1.13; 95% CI, 1.08–1.18; moderate certainty) and hypernatremia (RR, 1.64; 95% CI, 1.32–2.03; moderate certainty) and may increase the risk of neuromuscular weakness (RR, 1.21; 95% CI, 1.01–1.45; low certainty). The dose-response analysis showed a reduction in mortality with corticosteroids with optimal dosing of approximately 260 mg/d of hydrocortisone (RR, 0.90; 95% CI, 0.83–0.98) or equivalent. CONCLUSIONS: We found that corticosteroids may reduce mortality and increase shock reversal but they may also increase the risk of hyperglycemia, hypernatremia, and neuromuscular weakness. The dose-response analysis indicates optimal dosing is around 260 mg/d of hydrocortisone or equivalent.
Utility of Intraoperative Cytokeratin-7 Immunostaining During Mohs Micrographic Surgery for Sebaceous Carcinoma
Steen, A. , Demer, Addison M. , Vidal, Nahid Y. , Crum, Olivia M.

Dermatologic Surgery | January 23, 2024 | Volume: 50 | Issue: 4 | Pages: 384-386

10.1097/dss.0000000000004084 | PMID 38261738 Get It

Improved Outcomes Associated With Teduglutide Use in Patients With Both Short Bowel Syndrome and Crohn’s Disease
Siu, Rex K. , Karime, Christian , Hashash, Jana G. , Kinnucan, Jami , Picco, Michael F., Farraye, Francis A. , Farraye, Francis A , Hashash, Jana G

Crohn's & Colitis 360 | January 23, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/crocol/otae007 | PMID 38352117 Get It

Abstract Introduction Crohn’s disease (CD) with short bowel syndrome (SBS) can present as chronic intestinal failure (CIF) often requiring nutritional support. Teduglutide is a treatment option for these patients. We investigated clinical outcomes of CD-CIF patients with SBS treated with teduglutide. Methods Adults with CD-CIF and SBS who received teduglutide were identified at a tertiary care academic center between 2012 and 2023. Data was collected retrospectively. Primary outcome measured was reduction in parenteral support (PS) by ≥20% volume, with PS defined as utilization of parenteral nutrition (PN) or intravenous fluids (IVF). Several secondary outcomes included immunosuppressive medication changes, subjective symptom improvement, and stool output. Results We identified 32 patients with CD-CIF and SBS receiving teduglutide. Comparing clinical outcomes before and after teduglutide, 26 of 32 patients achieved the primary outcome of ≥20% PS reduction. A decrease was seen in patients requiring PN + IVF, with corresponding increases in patients requiring PN only and IVF only. Among all 3 groups, a total of 23 patients received PN prior to teduglutide, which decreased to 14 following teduglutide. Weekly PN volume reduced from 7.00 to 3.55 L and weekly frequency decreased from 7.00 to 3.00 instances (P < .01). Reductions in weekly volume and frequency were observed among all patients receiving IVF support (25 vs 15). Secondary outcomes showed improvement in patient reported subjective symptoms (84.4%), stool output (90.6%), patients meeting criteria for diarrhea/high ostomy output (27 vs 14), and use of unique antidiarrheal medications (3.0 vs 2.0). Conclusions This retrospective case series demonstrated improved clinical outcomes in patients with CD-CIF and SBS treated with teduglutide resulting in decreased PS requirements, antidiarrheal medications requirement, and stool output without significant effects on immunosuppressive therapy.
Possible improvements in effective fill factor using X‐ray fluorescent interpixel reflectors
Hsieh, Scott S.

Medical Physics | January 23, 2024 | Volume: 51 | Issue: 3 | Pages: 1617-1625

10.1002/mp.16944 | PMID 38259109 Get It

AbstractBackgroundThe spatial resolution of energy‐integrating diagnostic CT scanners is limited by interpixel reflectors on the detector, which optically isolate pixels but create dead space. Because the width of the reflector cannot easily be decreased, fill factor diminishes as resolution increases.PurposeWe propose loading (or mixing) a high‐Z element into the reflectors, causing the reflectors to be X‐ray fluorescent. Re‐emitted characteristic X‐rays could be detected in adjacent pixels, increasing the effective fill factor and compensating for fill factor loss with higher‐resolution detectors. The purpose of this work is to understand the physical principles of this approach and to analyze its effectiveness using Monte Carlo simulations.MethodsDetector pixels were modeled using the GEANT4 Monte Carlo package. The width of the reflector was kept constant at 0.1 mm throughout, and we considered pixel pitches between 0.5 and 1 mm. The pixelated scintillator material was gadolinium oxysulfide, 3 mm thick. The baseline reflector material was chosen to be acrylic, and varying concentrations of a high‐Z element were loaded into the material. We assumed that the optical characteristics of pixels were ideal (no absorption within pixels, perfect reflection at boundaries). The detector was irradiated uniformly with 10,000 X‐ray photons to estimate its spectral response. The figure of merit was the variance of the detector signal at zero frequency normalized to that of an ideal single‐bin photon‐counting detector with 100% fill factor. Sensitivity analyses were conducted to understand the effect of varying the high‐Z element concentration and the spectrum.ResultsInitial simulations suggested that a k‐edge near 50 keV would be ideal. Gd was therefore selected as the high‐Z material. The relative variances for a conventional energy integrating detector without Gd at 1 mm pixel pitch (81% fill factor) and 0.5 mm pixel pitch (64% fill factor) were 1.38 and 1.74, compared to 1.00 for an ideal photon counting detector, implying a 26% variance penalty for 0.5 mm pitch. When 1 g/cm3 Gd was loaded into the interpixel reflector, the relative variance improved to 1.27 and 1.43, respectively, implying that the variance penalty for including Gd together with 0.5 mm pitch is only 4%. Performance was nearly maximized at 1.0 g/cm3 of Gd, but a concentration of 0.5 g/cm3 of Gd showed most of the benefit. Improvements depend weakly on kV, with lower kV associated with higher improvements. An external anti‐scatter grid was not modeled in our simulations and would reduce the expected benefit, depending greatly on the pitch and dimensionality of the anti‐scatter grid.ConclusionsThe losses in fill factor associated with smaller pixel pitch can be reduced if Gd or a similar element could be loaded into the interpixel reflector. These improvements in noise efficiency are yet to be verified experimentally.
Characterization of the Pneumocystis jirovecii and Pneumocystis murina phosphoglucomutases (Pgm2s): a potential target for Pneumocystis therapy
Kottom, Theodore J. , Carmona, Eva M. , Limper, Andrew H. , Carmona, Eva M , Limper, Andrew H , Kottom, Theodore J

Antimicrobial Agents and Chemotherapy | January 23, 2024 | Volume: 68 | Issue: 3 | Pages: No page available

10.1128/aac.00756-23 | PMID 38259086 Get It

ABSTRACT Pneumocystis cyst life forms contain abundant β-glucan carbohydrates, synthesized using β-1,3 and β-1,6 glucan synthase enzymes and the donor uridine diphosphate (UDP)-glucose. In yeast, phosphoglucomutase (PGM) plays a crucial role in carbohydrate metabolism by interconverting glucose 1-phosphate and glucose 6-phosphate, a vital step in UDP pools for β-glucan cell wall formation. This pathway has not yet been defined in Pneumocystis . Herein, we surveyed the Pneumocystis jirovecii and Pneumocystis murina genomes, which predicted a homolog of the Saccharomyces cerevisiae major PGM enzyme. Furthermore, we show that PjPgm2p and PmPgm2p function similarly to the yeast counterpart. When both Pneumocystis pgm2 homologs are heterologously expressed in S. cerevisiae pgm2Δ cells, both genes can restore growth and sedimentation rates to wild-type levels. Additionally, we demonstrate that yeast pgm2Δ cell lysates expressing the two Pneumocystis pgm2 transcripts individually can restore PGM activities significantly altered in the yeast pgm2Δ strain. The addition of lithium, a competitive inhibitor of yeast PGM activity, significantly reduces PGM activity. Next, we tested the effects of lithium on P. murina viability ex vivo and found the compound displays significant anti- Pneumocystis activity. Finally, we demonstrate that a para-aryl derivative (ISFP10) with known inhibitory activity against the Aspergillus fumigatus PGM protein and exhibiting 50-fold selectivity over the human PGM enzyme homolog can also significantly reduce Pmpgm2 activity in vitro . Collectively, our data genetically and functionally validate phosphoglucomutases in both P. jirovecii and P. murina and suggest the potential of this protein as a selective therapeutic target for individuals with Pneumocystis pneumonia.
Effect of Bacille Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer After Prostate Radiotherapy
Durant, Adri , Lee, Yeonsoo Sara , Mi, Lanyu , Tyson, Mark D. , Durant, Adri M, Lee, Yeonsoo S, Tyson Ii, Mark D, Sara Lee, Yeonsoo , Faraj, Kassem , Lyon, Timothy D. , Singh, Parminder Pal

Bladder Cancer | January 23, 2024 | Volume: 10 | Issue: 1 | Pages: 35-45

10.3233/blc-230073 | PMID 38993532 Get It

BACKGROUND: Little is known about the impact of prior prostate radiation therapy (RT) on the Bacille Calmette-Guerin (BCG) immunotherapy response in patients with non-muscle invasive bladder cancer (NMIBC). OBJECTIVE: We hypothesized that the damaging radiation effects on the bladder could negatively influence BCG efficacy. METHODS: Men with a history of high-risk NMIBC were identified within the Surveillance, Epidemiology, and End Results–Medicare database. All patients completed adequate BCG defined as at least 5 plus 2 treatments completed within 12 months. Patients were stratified into 2 groups: with prior RT for prostate cancer and without prior RT before the diagnosis of NMIBC. The primary endpoint was a 5-year composite for progression defined as disease progression requiring systemic chemotherapy, checkpoint inhibitors, radical or partial cystectomy, or cancer-specific death. RESULTS: We identified 3,466 patients with NMIBC, including 145 with prior RT for prostate cancer. Five-year progression occurred in 471 patients (13.6%). Patients with prior RT were older than patients without prior RT (77.0 vs 75.0 years; P < .001). The distribution of T stage was significantly different at diagnosis between the RT and non-RT groups (RT: Ta, 44.8%; Tis, 18.6%; T1, 36.6%; without RT: Ta, 40.9%; Tis, 10.8%; T1, 48.3%; P = .002). No difference in the risk of total progression was observed between patients with and without prior RT ( P = .67). Similarly, no difference was observed after multivariable adjustment (hazard ratio, 0.99; 95% CI, 0.61-1.58; P = .95). CONCLUSION: For patients with NMIBC who undergo adequate BCG treatment, prior RT for prostate cancer was not associated with worse 5-year progression-free survival.
Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis
Barbour, Sean J. , Coppo, Rosanna , Er, Lee, Pillebout, Évangéline , Russo, María Luisa , Alpers, Charles E. , Ferrario, Franco, Jennette, J. Charles , Roberts, Ian S.D. , Cook, H. Terence , Ding, Jie , Su, Baige , Zhong, Xuhui, Zand, Ladan , Lucchetti, Laura , Katafuchi, Ritsuko , Shima, Yuko , Yoshikawa, Norishige, Ichikawa, Daisuke , Suzuki, Yusuke , Park, Catherine , Nelson, Raoul D., Narus, JoAnn Hansen , Wenderfer, Scott E. , Monteiro, Renato C. , Nakatani, Shinya , Mastrangelo, Antonio , Nuutinen, Matti, Koskela, Mikael , Weber, Lutz T. , Hackl, Ágnes, Pecoraro, Carmine, Yokoo, Takashi , Ito, Takafumi, Conti, Giovanni , Materassi, Marco , Zhang, Hong , Shi, Sufang , Liu, Zhihong , Ávila-Casado, Carmen , Bajema, Ingeborg M., Barreca, Antonella , Comstock, Jessica, Cornea, Virgilius , Eldin, Karen W. , Hernandez, Loren Herrera, Hou, Jean , Lin, Mercury, Messias, Nidia , Tokola, Heikki , DʼArmiento, Maria , Sannier, Aurélie , Jennette, J Charles , Ding, Jie , Zand, Ladan , Peruzzi, Licia , Shima, Yuko , Ichikawa, Daisuke , Suzuki, Yusuke , Narus, JoAnn H , Wenderfer, Scott E , Geetha, Duvuru , Daugas, Eric , Monteiro, Renato C , Tsuboi, Nobuo , Yokoo, Takashi , Fujimoto, Shouichi , Materassi, Marco , Shi, Sufang , Liu, Zhi-Hong , Tesar, Vladimir , Maixnerova, Dita , Barreca, Antonella , Eldin, Karen , Joh, Kensuke , Muda, Andrea Onetti , Pagni, Fabio , Diomedi-Camassei, Francesca , Tokola, Heikki , Seidl, Maximilian , Sannier, Aurélie , Soares, Maria Fernanda , Wang, Suxia , Zeng, Caihong , Coppo, Rosanna , Fogo, Agnes B. , Fervenza, Fernando C. , Murer, Luisa , Wyatt, Robert J. , Pohl, Martin, Santoro, Domenico , Tesař, Vladimı́r , Becker, Jan Ulrich , Diomedi‐Camassei, Francesca , Rosenberg, Avi Z. , Haas, Mark

Clinical Journal of the American Society of Nephrology | January 23, 2024 | Volume: 19 | Issue: 4 | Pages: 438-451

10.2215/cjn.0000000000000398 | PMID 38261310 Get It

Background Nephritis is a common manifestation of IgA vasculitis and is morphologically indistinguishable from IgA nephropathy. While MEST-C scores are predictive of kidney outcomes in IgA nephropathy, their value in IgA vasculitis nephritis has not been investigated in large multiethnic cohorts. Methods Biopsies from 262 children and 99 adults with IgA vasculitis nephritis ( N =361) from 23 centers in North America, Europe, and Asia were independently scored by three pathologists. MEST-C scores were assessed for correlation with eGFR/proteinuria at biopsy. Because most patients ( N =309, 86%) received immunosuppression, risk factors for outcomes were evaluated in this group using latent class mixed models to identify classes of eGFR trajectories over a median follow-up of 2.7 years (interquartile range, 1.2–5.1). Clinical and histologic parameters associated with each class were determined using logistic regression. Results M, E, T, and C scores were correlated with either eGFR or proteinuria at biopsy. Two classes were identified by latent class mixed model, one with initial improvement in eGFR followed by a late decline (class 1, N =91) and another with stable eGFR (class 2, N =218). Class 1 was associated with a higher risk of an established kidney outcome (time to ≥30% decline in eGFR or kidney failure; hazard ratio, 5.84; 95% confidence interval, 2.37 to 14.4). Among MEST-C scores, only E1 was associated with class 1 by multivariable analysis. Other factors associated with class 1 were age 18 years and younger, male sex, lower eGFR at biopsy, and extrarenal noncutaneous disease. Fibrous crescents without active changes were associated with class 2. Conclusions Kidney outcome in patients with biopsied IgA vasculitis nephritis treated with immunosuppression was determined by clinical risk factors and endocapillary hypercellularity (E1) and fibrous crescents, which are features that are not part of the International Study of Diseases of Children classification.
The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages
Hracs, Lindsay , Gorospe, Julia, Buie, Michael , Quan, Joshua , Goddard, Quinn , Caplan, Léa , Markovinović, Ante , Abbey, Yvonne , Abdullah, Murdani , Balderramo, Domingo , Bernstein, Çharles N. , Burisch, Johan , Chong, Vui Heng , Dotan, Iris , Ouali, Sara El , Forss, Anders, Dao, Hang Viet , Baños, Fabián Juliao , Kaibullayeva, Jamilya , Kobayashi, Taku , Miao, Yinglei , Ng, Ka Kei , Olén, Ola , Simadibrata, Marcellus , Sun, Yang , Turner, Dan , Vergara, Beatriz, Wei, Shu Chen, Yang, Suk‐Kyun , Kobayashi, Taku , Kaplan, Gilaad G. , Windsor, Joseph W. , Cummings, Michael K. , Coward, Stephanie B. , Williamson, Tyler S. , Abreu, María T. , Ahuja, Vineet , Ali, Raja Affendi Raja , Altuwaijri, Mansour A. , Banerjee, Rupa , Benchimol, Eric I. , Bernstein, Charles Noah , Brunet, Eduard , Dutta, Usha , Forbes, Angela J. , Forss, Anders, Gearry, Richard B. , Hartono, Juanda Leo , Hilmi, Ida Normiha , Hodges, Phoebe , Jones, Gareth‐Rhys , Kelly, Paul , Kotze, Paulo Gustavo , Lakatos, Péter L. , Lees, Charlie W. , Limsrivilai, Julajak , Lo, Bobby Zhao Sheng , Loftus, Edward V. , Ludvigsson, Jonas F. , Mak, Joyce Wing Yan , Okabayashi, Shinji , Panaccione, Remo , Paudel, Mukesh Sharma , Quaresma, Abel Botelho , Rubin, David T. , Suzuki, Hidekazu , Toro, Martín , Wei, Shu Chen, Yamamoto-Furusho, Jesus , Ng, Siew C.

No container title available | January 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3846147/v1 Get It

Abstract During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD.
Small RNA Changes in Plasma Have Potential for Early Diagnosis of Alzheimer’s Disease before Symptom Onset
Palade, Joanna , Alsop, Eric , Courtright-Lim, Amanda , Keuren‐Jensen, Kendall Van , Palade, Joanna , Hsieh, Michael, Whitsett, Timothy G. , Galasko, Douglas

Cells | January 23, 2024 | Volume: 13 | Issue: 3 | Pages: 207

10.3390/cells13030207 | PMID 38334599 Get It

Alzheimer’s disease (AD), due to its multifactorial nature and complex etiology, poses challenges for research, diagnosis, and treatment, and impacts millions worldwide. To address the need for minimally invasive, repeatable measures that aid in AD diagnosis and progression monitoring, studies leveraging RNAs associated with extracellular vesicles (EVs) in human biofluids have revealed AD-associated changes. However, the validation of AD biomarkers has suffered from the collection of samples from differing points in the disease time course or a lack of confirmed AD diagnoses. Here, we integrate clinical diagnosis and postmortem pathology data to form more accurate experimental groups and use small RNA sequencing to show that EVs from plasma can serve as a potential source of RNAs that reflect disease-related changes. Importantly, we demonstrated that these changes are identifiable in the EVs of preclinical patients, years before symptom manifestation, and that machine learning models based on differentially expressed RNAs can help predict disease conversion or progression. This research offers critical insight into early disease biomarkers and underscores the significance of accounting for disease progression and pathology in human AD studies.